Revamped Manufacturing Process Yields Fast-Track Ryplazim Approval Three Years Later
Executive Summary
Plasminogen therapy for unmet need licensed after Prometic took the time to develop a manufacturing process it could validate.
You may also be interested in...
Keeping Track: US FDA Approval Binge Includes Brexafemme, Wegovy, Ryplazim, Truseltiq, Lybalvi, Tembexa
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
BARDA Expands US Domestic Production Of Single-Use Systems For Vaccine Manufacturing
FlexBiosys wins award; others to follow. New capacity may also benefit manufacture of monoclonal antibodies and cell and gene therapies.
Communication Is Key In Adapting Production To Pandemic Component Supply Disruptions
US FDA is looking at risk-based approach for reporting changes in out-of-stock components such as plastic bioreactor bags, filters and tubing sets that are in short supply.